Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CDT1656
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Conduit Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Conduit, Agility Life Sciences Collaborate on Autoimmune Pipeline Formulations
Details : The partnership aims to develop new solid oral-dosage form products of its autoimmune pipeline for use in future clinical trials, which includes CDT1656 for treating autoimmune diseases.
Product Name : CDT1656
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 22, 2025
Lead Product(s) : CDT1656
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Conduit Pharma
Deal Size : Undisclosed
Deal Type : Partnership